FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

U.S. R&D headcount tumbles in key categories

Tools

Pharmalot has been crunching the numbers for R&D jobs and concludes that the U.S. is seeing a considerable amount of shrinkage in the field. Looking at new numbers from PhRMA for 2006, R&D employment among its members dropped 3.9 percent. And there were a number of sizable reductions last year, with the axe expected to drop again over the course of 2008.

RPM concludes that the biggest cutbacks in R&D are occurring in the approval and post-marketing phases. The money spent on R&D in the U.S. continues to rise, but after an 11.3 percent hike in 2006 budgets rose only 2.7 percent to a still considerable $35.4 billion.

- read the report from Pharmalot
- see the PhRMA report (.pdf)

Related Articles:
Top 8 layoffs of 2007
The Top 15 R&D Budgets
Big Pharma's biotech shift means layoffs for chemists
Ranks of sales reps thinning

More stories about sales and marketing   R&D budget   Phrma   pharmaceuticals   layoffs   R&D spending   job cuts  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.